Tags

Type your tag names separated by a space and hit enter

Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.
Epilepsy Behav. 2017 05; 70(Pt B):349-354.EB

Abstract

Recent interest for the use of cannabis-derived products as therapeutic agents in the treatment of epilepsies has necessitated a reevaluation of their effects on brain and behavior. Overall, prolonged cannabis use is thought to result in functional and structural brain alterations. These effects may be dependent on a number of factors: e.g., which phytocannabinoid is used (e.g., cannabidiol (CBD) vs. tetrahyrocannabinol (THC)), the frequency of use (occasional vs. heavy), and at what age (prenatal, childhood, adulthood) the use began. However, due to the fact that there are over seven hundred constituents that make up the Cannabis sativa plant, it is difficult to determine which compound or combination of compounds is responsible for specific effects when studying recreational users. Therefore, this review focuses only on the functional MRI studies investigating the effects of specific pharmacological preparations of cannabis compounds, specifically THC, tetrahydrocannabivarin (THCV), and CBD, on brain function in healthy individuals and persons with epilepsy with references to non-epilepsy studies only to underline the gaps in research that need to be filled before cannabis-derived products are considered for a wide use in the treatment of epilepsy. This article is part of a Special Issue entitled "Cannabinoids and Epilepsy".

Authors+Show Affiliations

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: jallendorfer@uabmc.edu.Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28109780

Citation

Allendorfer, Jane B., and Jerzy P. Szaflarski. "Neuroimaging Studies Towards Understanding the Central Effects of Pharmacological Cannabis Products On Patients With Epilepsy." Epilepsy & Behavior : E&B, vol. 70, no. Pt B, 2017, pp. 349-354.
Allendorfer JB, Szaflarski JP. Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. Epilepsy Behav. 2017;70(Pt B):349-354.
Allendorfer, J. B., & Szaflarski, J. P. (2017). Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. Epilepsy & Behavior : E&B, 70(Pt B), 349-354. https://doi.org/10.1016/j.yebeh.2016.11.020
Allendorfer JB, Szaflarski JP. Neuroimaging Studies Towards Understanding the Central Effects of Pharmacological Cannabis Products On Patients With Epilepsy. Epilepsy Behav. 2017;70(Pt B):349-354. PubMed PMID: 28109780.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. AU - Allendorfer,Jane B, AU - Szaflarski,Jerzy P, Y1 - 2017/01/18/ PY - 2016/10/31/received PY - 2016/11/11/revised PY - 2016/11/14/accepted PY - 2017/1/23/pubmed PY - 2018/1/18/medline PY - 2017/1/23/entrez KW - Cannabidiol (CBD) KW - Cannabis KW - Epilepsy KW - Functional MRI (fMRI) KW - Tetrahydrocannabinol (THC) KW - Tetrahydrocannabivarin (THCV) SP - 349 EP - 354 JF - Epilepsy & behavior : E&B JO - Epilepsy Behav VL - 70 IS - Pt B N2 - Recent interest for the use of cannabis-derived products as therapeutic agents in the treatment of epilepsies has necessitated a reevaluation of their effects on brain and behavior. Overall, prolonged cannabis use is thought to result in functional and structural brain alterations. These effects may be dependent on a number of factors: e.g., which phytocannabinoid is used (e.g., cannabidiol (CBD) vs. tetrahyrocannabinol (THC)), the frequency of use (occasional vs. heavy), and at what age (prenatal, childhood, adulthood) the use began. However, due to the fact that there are over seven hundred constituents that make up the Cannabis sativa plant, it is difficult to determine which compound or combination of compounds is responsible for specific effects when studying recreational users. Therefore, this review focuses only on the functional MRI studies investigating the effects of specific pharmacological preparations of cannabis compounds, specifically THC, tetrahydrocannabivarin (THCV), and CBD, on brain function in healthy individuals and persons with epilepsy with references to non-epilepsy studies only to underline the gaps in research that need to be filled before cannabis-derived products are considered for a wide use in the treatment of epilepsy. This article is part of a Special Issue entitled "Cannabinoids and Epilepsy". SN - 1525-5069 UR - https://www.unboundmedicine.com/medline/citation/28109780/Neuroimaging_studies_towards_understanding_the_central_effects_of_pharmacological_cannabis_products_on_patients_with_epilepsy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1525-5050(16)30622-9 DB - PRIME DP - Unbound Medicine ER -